RecruitingNot ApplicableNCT07045688

Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection

Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection


Sponsor

Sohag University

Enrollment

150 participants

Start Date

May 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .


Eligibility

Min Age: 19 Years

Inclusion Criteria2

  • Age: >18 years old.
  • H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test).

Exclusion Criteria5

  • Prior H. pylori treatment: Previous treatment for H. pylori infection.
  • Allergies: Known allergies to study medications or components.
  • Patients cannot finish treatment course.
  • Patient missed follow up.
  • Patients refusing or neglecting test of cure for H. pylori.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEfficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection

we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.

DRUGEfficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection

we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.

DRUGEfficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection

we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.


Locations(1)

Sohag University Hospital

Sohag, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07045688


Related Trials